



E&P Small Cap Healthcare Conference



Healing. Redefined.

September 12, 2023

This presentation has been prepared by PolyNovo Limited and is provided for general information purposes only. No party other than PolyNovo has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. PolyNovo Limited makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. PolyNovo and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, or contained in or derived from, or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of PolyNovo. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by PolyNovo or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

NovoSorb[®]

Genius technology

Underserved market

Capital efficient **Growth** and
Scaling


Innovation driven out of frustration with the Existing Standard of Care

2002

The Bali bombing killed 202, critically injured 209. Australian survivors were repatriated to major Burns units for treatment. Large, delayed and colonized wounds required dermal substitutes, but the prevalent biological SOC carried risk of infection and rejection. Prof. John Greenwood (Burns Unit, Royal Adelaide Hospital) sought a synthetic alternative



Australian research agency CSIRO developed a family of polymers -- synthetic material that could safely biodegrade and be metabolized by the human body -- for use in implantable medical devices.



Innovating and Disrupting US \$2.4 B Advanced Skin Substitute Market



**Critical need:
underserved
category**

Advanced Skin Substitutes and tissue regeneration solutions are needed globally. Many products in this category are fraught with issues around tissue origin, complex supply chain and manufacturing, regulatory and licensing challenges and religious considerations, leading to restricted global access. Additionally, with most solutions, there are considerations around OR use, infection and pain associated with dressing change. The complex value chain drives associated costs, making many products expensive and out of reach for many societies. Advanced Skin Substitutes and tissue regeneration solutions cater to ~ 800 M / 8 B population today.



**Simple, yet
transformative
solution**

NovoSorb BTM was designed by a Burn Surgeon and Polymer chemist as an immunologically inert, biocompatible dermal foam, designed to resorb after enabling body's natural healing process. It has consistently demonstrated excellent outcomes, including restoration of form and function and a dramatically improved cosmesis for patient at a much lower complexity for the operating team. It is designed for manufacturability and global scale at a much lower cost versus current standard of care in the US\$2.4 B advanced skin substitute market*



**Approved
products, rapidly
increasing global
presence**

Genius technology with a robust portfolio of intellectual property and trade secrets (61 issued patents, including on drug and antimicrobial elution, through 2038)

- BTM®: FDA cleared in 2015, registered and sold in 27 countries globally
- MTX®: FDA cleared in 2022



**Attractive business
profile**

NovoSorb BTM is already a Standard of Care for burns and market leader in Australia, New Zealand, Germany, United Kingdom and on its way to become the standard of care for burns and trauma in USA. Since Jan 2021, a 120 patient Burns Pivotal RCT is underway, in partnership with US FDA and BARDA. Over 80+ independent and peer reviewed publications and case series have driven rapid adoption of NovoSorb around the world.



**Capital efficient,
profitable, hyper
growth**

Simple manufacturing footprint, ready for global scaling. Clearly demonstrable outcomes, Professional enthusiasm and word of mouth coupled with lean focused execution is driving hypergrowth. PolyNovo, USA is already a profitable EBITDA business. Post successful capital raise in Nov 2022, the business has ~ US \$ 40 MM plus in cash and equivalent, with minimal cash burn. Geography, Channel and/or specific indication alliances are expected to open door to multi-billion-dollar opportunities.



NovoSorb®: Simple. Elegant. Transformative

Macro to Micro wounds:

NovoSorb BTM's matrix organizes a large wound (macrowound) into a series of interconnected small wounds (microwounds). The body easily heals small wounds, promoting organized, regenerative healing.

- Biocompatible
- Resorbable

Optimized Regenerative Healing





- 100% synthetic, maintains integrity over time and resistant to shear forces.
- Clinically shown to be robust in presence of infection.
- Flexible, allowing clinicians to skin graft at their convenience, in stages or all at once.
- Virtually unlimited in its supply or consistency unlike biologics.
- Used by a variety of Surgeons including Plastic, Reconstructive, Trauma and General

Minimizes scarring. Restores form and function.

Robust IP Portfolio


PolyNovo has obtained IP Protection for its 10 Patent families (incl. 61 patents & 28 patent applications) in a broad range of countries including commercial destinations. These incl. protection for compositions of matter, as well as their general & specific medical use in applications including stents, orthopedic repair, burns & wound repair, hernia, diabetic ulcer & breast reconstruction. The patents and applications are fully owned by PolyNovo, providing protection for company's technologies until as far out as **2038**.



NovoSorb® Will Disrupt Several Attractive Addressable Markets

POLYNOVO FOCUS


Trauma (P&R)
Global incidence:
78.2 MM



Burns (Deep dermal/FT/PT/ST)
Global incidence:
8.9 MM

WORKING WITH ALLIANCES

Hernia/other reconstruction
Global procedures:
8.9 MM





Orthobiologics
Global procedures:
2.2 MM

Breast reconstruction
Global procedures:
155 M

Source : Global Data, Zion reports, 2021, WHO, Government sources
M – 000; MM – 000,000; B – Billion


Global Strategy on a Page:

Focused on Burns & Trauma – Working with alliances in adjacencies



Disciplined Execution

Yielding Strong Business Results and Redefining the Standard of Care




* Seeking alliances

US FDA has cleared NovoSorb BTM wound dressing for management of wounds including: partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic and vascular ulcers, surgical wounds(donor sites/grfts, post Moh's surgery, post-laser surgery, podiatric, wound dehiscence), Trauma wounds(abrasions, lacerations, second degree burns and skin tears) and draining wounds


Next Generation Dermal Substitute




Total Employees



Customers (Hospitals)



Total Revenue A\$



➔ Team expansion

➔ New applications

ANZ ➔ U.S. ➔ UK/I ➔ Germany ➔ Canada ➔ Hong Kong ➔ India ➔ Spain ➔ France ➔ **Japan** ➔ **China**

Uniquely situated to drive Global leadership and impact


- **Genius Technology:** Product to Procedure & Platform
- **Underserved market :** From 800m to 7.2B people
- **Committed to Capital Efficient Growth & Scaling**

Purpose driven, Engaged organization

- Building **Global Organization, Processes** and **Technology spine** to enable scale

Next Generation Dermal Substitute

- **Customers** helping us drive **adoption curve** and **market development**





Thank you